R.S. V. R.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 3 Randomized Study of Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
- Phase II Multicenter Trial of Ibrutinib and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia with/without TP53 Aberrations
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
Data & Insights
Has run more than one trial at 133 of 339 partner sites.
Specializations
Lymphoma Research Focus
This investigator specializes in various types of lymphoma, with particular emphasis on advanced treatment protocols. Their research encompasses Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, and Mantle Cell Lymphoma.
- Advanced Stage Hodgkin Lymphoma Management
- DLBCL Treatment Optimization
- Follicular and Marginal Zone Lymphoma Therapy
Key interests include PET-adapted therapy approaches and combination treatment strategies involving targeted therapeutics.
Melanoma Studies
The investigator conducts research in advanced and metastatic melanoma treatment approaches, with specific focus on immunotherapy interventions and targeted therapeutic strategies.
- Stage III Melanoma Management
- Immunotherapy Response Assessment
- Neoadjuvant Treatment Approaches
Research activities concentrate on treatment optimization and response monitoring in melanoma patients.
Therapeutic Innovation
The investigator explores novel therapeutic combinations including targeted therapies and immunotherapy agents across multiple hematologic malignancies.
- Combination Therapy Development
- Treatment Response Assessment
- Novel Drug Applications
Focus areas include treatment adaptation strategies and therapeutic response optimization.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.